Stock RZLT REZOLUTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Rezolute, Inc.

Equities

RZLT

US76200L3096

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
2.99 USD +4.91% Intraday chart for Rezolute, Inc. -9.67% +201.26%
04-18 JonesTrading Starts Rezolute With Buy Rating, $10 Price Target MT
03-06 Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
REZOLUTE, INC. - PHASE 2 RIZE STUDY SUB-ANALYSES TO BE PRESENTED AT THE 2024 PEDIATRIC ENDOCRINE SOCIETY ANNUAL MEETING
AQ
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
GL
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
AQ
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA
AQ
Rezolute : Corporate Presentation – March 2024
PU
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
GL
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
AQ
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
GL
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
AQ
REZOLUTE RECEIVES INNOVATION PASSPORT DESIGNATION FROM THE U.K. INNOVATIVE LICENSING AND ACCESS PATHWAY STEERING GROUP FOR RZ358
AQ
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
GL
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
GL
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
GL
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
NE
REZOLUTE TO PARTICIPATE IN BTIG'S 3RD ANNUAL OPHTHALMOLOGY DAY
AQ
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
GL
Rezolute Reports First Quarter Fiscal 2024 Results
GL
REZOLUTE RECEIVES PRIORITY MEDICINES ELIGIBILITY FROM EUROPEAN MEDICINES AGENCY FOR ENHANCED REGULATORY SUPPORT OF RZ358 IN CONGENITAL HYPERINSULINISM
AQ
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RZLT Stock
  4. News Rezolute, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW